Foundayo: New Oral Weight-Loss Pill Approved

0:00It's April 1st. Welcome to Global News Today, powered by AI. I'm Cory with the story. Federal regulators just greenlit Eli Lilly's latest weight loss pill, or for Glypron, branded as Foundaio. It's the second daily or option for obesity in related issues, working like those popular injections by mimicking a hormone that curbs hunger and... boosts fullness. Shipping kicks off Monday, with insured folks potentially grabbing it for as low as $25 a month via a Lilly discount card. Caspairs will see prices from $149 up to $349 monthly, based on dose. This joins Novel Nordisk's Oral Wegovi, which has racked up over 600,000 prescriptions in the U.S. since December. Folks are buzzing about the convenience of these pills over shots, and studies show or for Glypron users dropped way sizes, lowered blood pressure, triglycerides, and cholesterol. Side effects hit mostly the gut, causing 5-10% to drop out, compared to 3% on placebo.

1:04The FDA fast-tracked it through a new program, reviewing the application in just 50 days. Unlike Wegovi's peptide that needs an empty stomach and water timing, this small molecule version has no such rules. Plus, it's set for a Trump-era deal to slash GOP-1 drug prices. Eli Lilly shares jumped over 4% on the news, signaling big market vibes as these Orals reshape weight management.